HomeCompareZLDAF vs YUM

ZLDAF vs YUM: Dividend Comparison 2026

ZLDAF yields 609.16% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZLDAF wins by $292137.21M in total portfolio value
10 years
ZLDAF
ZLDAF
● Live price
609.16%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$292137.32M
Annual income
$220,826,387,190.95
Full ZLDAF calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — ZLDAF vs YUM

📍 ZLDAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZLDAFYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZLDAF + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZLDAF pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZLDAF
Annual income on $10K today (after 15% tax)
$51,778.75/yr
After 10yr DRIP, annual income (after tax)
$187,702,429,112.31/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, ZLDAF beats the other by $187,702,395,148.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZLDAF + YUM for your $10,000?

ZLDAF: 50%YUM: 50%
100% YUM50/50100% ZLDAF
Portfolio after 10yr
$146068.71M
Annual income
$110,413,213,574.13/yr
Blended yield
75.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ZLDAF
No analyst data
Altman Z
-200.0
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZLDAF buys
0
YUM buys
0
No recent congressional trades found for ZLDAF or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZLDAFYUM
Forward yield609.16%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$292137.32M$107.0K
Annual income after 10y$220,826,387,190.95$39,957.33
Total dividends collected$286203.91M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: ZLDAF vs YUM ($10,000, DRIP)

YearZLDAF PortfolioZLDAF Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$71,616$60,916.18$10,980$280.44+$60.6KZLDAF
2$484,347$407,718.13$12,185$435.72+$472.2KZLDAF
3$3,095,297$2,577,045.67$13,722$684.14+$3.08MZLDAF
4$18,703,566$15,391,597.96$15,773$1,090.14+$18.69MZLDAF
5$106,933,266$86,920,450.25$18,650$1,773.02+$106.91MZLDAF
6$578,855,369$464,436,774.20$22,921$2,966.37+$578.83MZLDAF
7$2,969,008,370$2,349,633,124.95$29,685$5,158.69+$2968.98MZLDAF
8$14,439,931,036$11,263,092,080.14$41,216$9,453.02+$14439.89MZLDAF
9$66,645,727,013$51,195,000,804.51$62,672$18,571.31+$66645.66MZLDAF
10$292,137,315,095$220,826,387,190.95$107,016$39,957.33+$292137.21MZLDAF

ZLDAF vs YUM: Complete Analysis 2026

ZLDAFStock

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Full ZLDAF Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ZLDAF vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZLDAF vs SCHDZLDAF vs JEPIZLDAF vs OZLDAF vs KOZLDAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.